Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
A considerable proportion of patients discontinue dipyridamole therapy because of headache. Risk indicators for the development of dipyridamole induced headache were identified by means of an exploratory analysis of data from the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) and the Second European Stroke Prevention Study (ESPS 2). In ESPRIT, dipyridamole induced headache was significantly associated with female sex, absence of hypertension and non-smoking (area under the receiver operator characteristic (ROC) curve 0.63 (95% CI 0.58 to 0.68)) and in ESPS 2 with female sex and absence of ischaemic lesions on imaging (area under the ROC curve 0.64 (95% CI 0.59 to 0.69)).
Halkes
P H A
PH
Department of Neurology, Rudolf Magnus Institute of Neuroscience and Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands. phalkes@umcutrecht.nl
van Gijn
J
J
Kappelle
L J
LJ
Koudstaal
P J
PJ
Algra
A
A
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002545:Brain Ischemia / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D002536:Cerebral Arteries / Q000473:pathology*; D004176:Dipyridamole / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006261:Headache / Q000139:chemically induced* / Q000453:epidemiology*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000453:epidemiology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012372:ROC Curve; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000453:epidemiology; D020521:Stroke / Q000517:prevention & control
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin